首页> 外文期刊>Osteoarthritis and cartilage >Parathyroid hormone (1-34) prevents cartilage degradation andpreserves subchondral bone micro-architecture in guinea pigs with spontaneous osteoarthritis
【24h】

Parathyroid hormone (1-34) prevents cartilage degradation andpreserves subchondral bone micro-architecture in guinea pigs with spontaneous osteoarthritis

机译:甲状旁腺激素(1-34)预防自发性骨关节炎的豚鼠软骨退化并保留软骨下骨微结构

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To assess whether parathyroid hormone (PTH) (1-34) could improve the micro-structure of subchondral bone, and retard cartilage degradation in a naturally occurring Osteoarthritis (OA) model. Design: Forty-eight 1-month-old guinea pigs were divided into two groups: 32 were treated by normal saline (NS) and sacrificed at 1, 3, 6 and 9 months of age; the other 16 received PTH (1-34) from 3 months, and were sacrificed at 6 and 9 months. Masson staining and the Osteoarthritis Research Society International (OARSI) grade scores were used to assess cartilage degradation. Immunohistochemistry analyses of type-II collagen, matrix metalloproteinases-13 (MMP-13) and sclerostin (SOST) in the cartilage, osteoprotegerin (OPG) and receptor activator of nuclear factor-kB ligand (RANKL) and PTH receptor (PTH1R) in the cartilage and subchondral bone were performed. Subchondral bone micro-architecture was assessed by micro-computed tomography (micro-CT). Results: Histological analyses revealed OA occurred at 3 months of age and was more severe with increasing age, and PTH (1-34) reduced the OARSI scores at 6 and 9 months of age. Micro-CT analysis indicated that PTH (1-34) treatment increased the bone volume ratio and bone mineral density (BMD), while retarding the subchondral trabecular bone micro-architectural changes from rod-like to plate-like. Immunohistochemical staining demonstrated that PTH (1-34) treatment increased type-II collagen expression and decreased SOST and MMP-13 expression in the cartilage, while elevating the PTH1R, OPG/RANKL expression ratio in the cartilage and subchondral trabecular bone when compared with the control groups. Conclusions: PTH (1-34) can prevent cartilage damage progression and retard the deterioration of subchondral trabecular bone in guinea pigs.
机译:目的:评估在自然发生的骨关节炎(OA)模型中,甲状旁腺激素(PTH)(1-34)是否可以改善软骨下骨的微结构并阻止软骨降解。设计:将48只1个月大的豚鼠分为两组:32只接受生理盐水(NS)处理,分别在1、3、6和9个月大时处死。另外16个婴儿在3个月内接受PTH(1-34),并在6个月和9个月时处死。使用Masson染色和国际骨关节炎研究学会(OARSI)评分来评估软骨退化。软骨中II型胶原,基质金属蛋白酶13(MMP-13)和硬化蛋白(SOST),骨保护素(OPG)以及核因子-kB配体的受体激活剂(RANKL)和PTH受体(PTH1R)的免疫组织化学分析进行软骨和软骨下骨。软骨下骨微结构通过微计算机断层扫描(micro-CT)进行评估。结果:组织学分析显示,OA在3个月大时发生,并且随着年龄的增长而变得更严重,PTH(1-34)降低了6和9个月大时的OARSI评分。 Micro-CT分析表明,PTH(1-34)处理可增加骨体积比和骨矿物质密度(BMD),同时阻止软骨下小梁骨微结构从杆状变为板状的变化。免疫组织化学染色显示,与PTH(1-34)处理相比,PTH(1-34)处理可增加II型胶原表达,并降低软骨中SOST和MMP-13表达,同时提高软骨和软骨下小梁骨中的PTH1R,OPG / RANKL表达比。对照组。结论:PTH(1-34)可以预防豚鼠软骨损伤的进展并延缓软骨下小梁骨的退化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号